Antev is a clinical-stage biopharmaceutical company focused on the development of a robust registration-ready data package in areas of unmet clinical need for men’s health: prostate cancer, benign prostatic hyperplasia (BPH) and acute urinary retention (AUR), and establishing value in women’s health indications: endometriosis and uterine fibroids.
We have a substantially differentiated product; a long-acting injectable gonadotrophin-releasing hormone (GnRH) antagonist with a novel microcrystal formulation, which is able to overcome the historical problems of previous GnRH antagonist candidates while also reducing injection site reactions.
We believe that the novel formulation, together with the advantages conferred by the drug class, and our experienced team of experts, have the potential to establish our product, teverelix TFA, as the gold standard treatment in its indications.
Since the establishment of Antev in 2013, we have been committed to the development of therapies in areas of unmet need in men’s health indications. Following the success of several phase II studies in advanced prostate cancer and benign prostatic hyperplasia (BPH), we have expanded our focus into women’s health indications.
The conditions we are targeting are common and reduce quality of life for those who suffer with them: our objective is to improve the lives of these patients. Our dedicated team of experts is compiling extensive preclinical and clinical data and streamlining our R&D and manufacturing processes to produce technologies that challenge the current treatment paradigm for these conditions.
We have attained a strong intellectual property estate and are expanding our patent protection to include our novel microcrystal formulation, indications, chemistry, manufacturing, and control (CMC) processes.
We are currently preparing phase III clinical programmes for our two lead indications, and we believe that our rigorous methodology, focused approach, and dedication puts us in a strong position to achieve our goal.